Boehringer Ingelheim

BI and Lilly's diabetes drug Jardiance reverses heart failure in animal models
BI and Lilly's diabetes drug Jardiance reverses heart failure in animal models
Fierce Biotech
Eli Lilly
Boehringer Ingelheim
Jardiance
type 2 diabetes
heart failure
Flag link:
BI chief “regrets” Brexit, but continues to invest in UK
BI chief “regrets” Brexit, but continues to invest in UK
Pharmaforum
UK
Brexit
Boehringer Ingelheim
Flag link:
PureTech, Boehringer partner to develop lymph node-targeting cancer immunotherapies
PureTech, Boehringer partner to develop lymph node-targeting cancer immunotherapies
BioCentury
Boehringer Ingelheim
PureTech
lymphatic targeting
GI cancers
Flag link:
Boehringer’s blockbuster Spiriva under pressure, profits down
Boehringer’s blockbuster Spiriva under pressure, profits down
Pharmaforum
Boehringer Ingelheim
earnings
Spiriva
Flag link:
Boehringer Ingelheim buys MacroDel platform developer ICD Therapeutics
Boehringer Ingelheim buys MacroDel platform developer ICD Therapeutics
Pharmaceutical Business Review
Boehringer Ingelheim
MacroDel biologics
M&A
ICD Therapeutics
Flag link:
Hand over your Humira biosim launch plans; judge tells Boehringer in AbbVie patent fight
Hand over your Humira biosim launch plans; judge tells Boehringer in AbbVie patent fight
Fierce Pharma
AbbVie
Boehringer Ingelheim
Humira
biosimilars
Flag link:
Boehringer Ingelheim and 3BP Forge a Multi-Year Collaboration
Boehringer Ingelheim and 3BP Forge a Multi-Year Collaboration
BioSpace
Boehringer Ingelheim
3B Pharmaceuticals
drug discovery
peptides
Flag link:
Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride
Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride
Pharmaceutical Business Review
Boehringer Ingelheim
Eli Lilly
glimepiride
linagliptin
Tradjenta
type 2 diabetes
clinical trials
Flag link:
Boehringer Ingelheim and IBM link up for blockchain-powered clinical trials in Canada
Boehringer Ingelheim and IBM link up for blockchain-powered clinical trials in Canada
Fierce Biotech
Boehringer Ingelheim
IBM
Canada
blockchain
clinical trials
Flag link:
AbbVie loses bid to hoard documents in Humira patent fight with Boehringer
AbbVie loses bid to hoard documents in Humira patent fight with Boehringer
Fierce Pharma
Boehringer Ingelheim
AbbVie
biosimilars
Humira
patents
Flag link:
Boehringer taps BioMed X to source psychiatric disease research proposals
Boehringer taps BioMed X to source psychiatric disease research proposals
BioCentury
Boehringer Ingelheim
BioMed
drug discovery
psychiatric disease
Flag link:
Boehringer building out biologics manufacturing in China
Boehringer building out biologics manufacturing in China
BioPharma Dive
China
drug manufacturing
Boehringer Ingelheim
biologics
Flag link:
Bioharmony, Boehringer partner to develop antimicrobials
Bioharmony, Boehringer partner to develop antimicrobials
BioCentury
Boehringer Ingelheim
Bioharmony Therapeutics
antimicrobials
Flag link:
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Flag link:
Boehringer offloads an mTOR cancer drug as Xynomic plots a quick advance in the clinic
Boehringer offloads an mTOR cancer drug as Xynomic plots a quick advance in the clinic
Endpoints
Boehringer Ingelheim
R&D
Xynomic
mTOR
Flag link:
Boehringer employees go door-to-door delivering holiday hope to lung cancer patients
Boehringer employees go door-to-door delivering holiday hope to lung cancer patients
Fierce Pharma
Boehringer Ingelheim
patients
lung cancer
Flag link:
Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus
Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus
Fierce Pharma
Sanofi
Lantus
Eli Lilly
Boehringer Ingelheim
Mylan Labs
generics
diabetes
insulin
basal insulin
Flag link:
Boehringer Ingelheim plans to cut about 300 jobs in France
Boehringer Ingelheim plans to cut about 300 jobs in France
Yahoo/Reuters
France
Boehringer Ingelheim
layoffs
Flag link:
Boehringer dropping ex-U.S. biosimilars programs
Boehringer dropping ex-U.S. biosimilars programs
BioCentury
Boehringer Ingelheim
biosimilars
Flag link:
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
BioSpace
cancer
breast cancer
lung cancer
drug approvals
AstraZeneca
Takeda
Ariad Pharmaceuticals
Merck
Pfizer
Novartis
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly
Puma Biotechnology
Mylan
Genentech
Flag link:

Pages